K
Kingo Chida
Researcher at Hamamatsu University School of Medicine
Publications - 342
Citations - 8246
Kingo Chida is an academic researcher from Hamamatsu University School of Medicine. The author has contributed to research in topics: Lung & Bronchoalveolar lavage. The author has an hindex of 50, co-authored 342 publications receiving 7527 citations. Previous affiliations of Kingo Chida include Hamamatsu University.
Papers
More filters
Journal ArticleDOI
Cumulative incidence of and predictive factors for lung cancer in IPF.
Yuichi Ozawa,Takafumi Suda,Tateaki Naito,Noriyuki Enomoto,Dai Hashimoto,Tomoyuki Fujisawa,Yutaro Nakamura,Naoki Inui,Hirotoshi Nakamura,Kingo Chida +9 more
TL;DR: The present study was conducted to elucidate the cumulative incidence and risk factors for lung cancer in IPF patients by retrospective longitudinal cohort analysis.
Journal ArticleDOI
Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer.
Yuzo Suzuki,Takafumi Suda,Kazuki Furuhashi,Masako Suzuki,Michio Fujie,Dai Hahimoto,Yutaro Nakamura,Naoki Inui,Hirotoshi Nakamura,Kingo Chida +9 more
TL;DR: Indoleamine 2,3-dioxygenase activity was increased in lung cancer patients, and higher IDO activity was associated with more advanced stages, suggesting that increasedIDO activity is involved in disease progression of lung cancer, possibly through its immunosuppressive effect.
Journal ArticleDOI
Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases
Takafumi Suda,Yusuke Kaida,Yutaro Nakamura,Noriyuki Enomoto,Tomoyuki Fujisawa,Shiro Imokawa,Hideo Hashizume,Tateaki Naito,Dai Hashimoto,Yasuo Takehara,Naoki Inui,Hirotoshi Nakamura,Thomas V. Colby,Kingo Chida +13 more
TL;DR: In this paper, the cumulative incidence of acute exacerbation (AE) in CVD-associated interstitial pneumonia (CVD-IP) and its clinical characteristics were investigated. And the authors found that age was an independent significant factor predicting AE.
Journal ArticleDOI
Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis
Takashi Ogura,Hiroyuki Taniguchi,Arata Azuma,Yoshikazu Inoue,Yasuhiro Kondoh,Yoshinori Hasegawa,Masashi Bando,Shinji Abe,Yoshiro Mochizuki,Kingo Chida,Matthias Klüglich,Tsuyoshi Fujimoto,Kotaro Okazaki,Yusuke Tadayasu,Wataru Sakamoto,Yukihiko Sugiyama +15 more
TL;DR: There was a trend toward lower exposure of nintedanib when it was added to pirfenidone in patients with idiopathic pulmonary fibrosis and further study is needed to evaluate the safety and tolerability profile.
Journal ArticleDOI
Antiinflammatory Roles of Peroxisome Proliferator–activated Receptor γ in Human Alveolar Macrophages
TL;DR: Data indicate that PPARgamma expressed by AMs play an antiinflammatory role through inhibiting cytokine production and increasing their CD36 expression together with the enhanced phagocytosis of apoptotic neutrophils, which is an essential process for the resolution of inflammation.